E. F. Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
E. F. Kim has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Array В. Филин
Russian Scientific Centre of Surgery named after Academician B.V. Petrovskiy, Ministry of Health of Russia
4 shared publications - Denis Y. Kachanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
3 shared publications - Elena V. Feoktistova
Russian Children’s Clinical Hospital – branch of the Pirogov Russian National Research Medical University, Moscow; Pirogov Russian National Research Medical University, Moscow
3 shared publications - Galina V. Tereshchenko
Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
3 shared publications - R. A. Moiseenko
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
3 shared publications - Svetlana R. Varfolomeeva
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
3 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by "MedINK" Publishing House
- Vol. 1 (2) , 73-79
Robot-assisted antegrade intersphincteric resection: A case from practice at the Moscow City Oncology Hospital No. 62
Background . Treatment of low tumors of the rectum remains one of the most complex oncological problems. If a tumor is ultra-low and specific anatomical characteristics of the pelvis are identified, organ-sparing surgery in the framework of the standard laparoscopic access becomes exacting due to rigidity of the instruments, while combined abdominoperineal resection is associated with additional risks. In robot-assisted access, the instruments have much higher motion degrees of freedom which allows to overcome difficulties caused by complex anatomy, size and site of the tumor. Aim . To demonstrate benefits of organ-sparing robot-assisted antegrade intersphincteric resection in patients with narrow and deep pelvis using a real clinical case. Clinical case . A 50‑year-old patient was admitted to the Oncological Proctology Division of the Moscow City Oncology Hospital No. 62 with adenocarcinoma of the lower rectal ampulla (cT3N1M0). Magnetic resonance imaging showed features of the pelvis making standard intervention difficult. Following neoadjuvant chemoradiotherapy without a significant pathological response, a fully transabdominal robot-assisted (da Vinci Xi) intersphincteric rectal resection was performed. Distinctive features of the procedure were absence of the perineal stage, colonic pull-through and delayed (on day 7) coloanal anastomosis formation without a temporary stoma. This technique allowed the avoid extirpation while achieving oncological radicality (ypT3N0R0). Functional outcomes at 6 months corresponded to a Wexner score of 12. Conclusion . This approach, based on strict magnetic resonance imaging data on the features of the pelvis allows to spare the anal sphincter preservation in patients with ultra-low tumors in the setting of challenging pelvic anatomy.
- 10 August 2026
- Published by "MedINK" Publishing House
- Vol. 1 (2) , 73-79
Open AccessRobot-assisted antegrade intersphincteric resection: A case from practice at the Moscow City Oncology Hospital No. 62
Background . Treatment of low tumors of the rectum remains one of the most complex oncological problems. If a tumor is ultra-low and specific anatomical characteristics of the pelvis are identified, organ-sparing surgery in the framework of the standard laparoscopic access becomes exacting due to rigidity of the instruments, while combined abdominoperineal resection is associated with additional risks. In robot-assisted access, the instruments have much higher motion degrees of freedom which allows to overcome difficulties caused by complex anatomy, size and site of the tumor. Aim . To demonstrate benefits of organ-sparing robot-assisted antegrade intersphincteric resection in patients with narrow and deep pelvis using a real clinical case. Clinical case . A 50‑year-old patient was admitted to the Oncological Proctology Division of the Moscow City Oncology Hospital No. 62 with adenocarcinoma of the lower rectal ampulla (cT3N1M0). Magnetic resonance imaging showed features of the pelvis making standard intervention difficult. Following neoadjuvant chemoradiotherapy without a significant pathological response, a fully transabdominal robot-assisted (da Vinci Xi) intersphincteric rectal resection was performed. Distinctive features of the procedure were absence of the perineal stage, colonic pull-through and delayed (on day 7) coloanal anastomosis formation without a temporary stoma. This technique allowed the avoid extirpation while achieving oncological radicality (ypT3N0R0). Functional outcomes at 6 months corresponded to a Wexner score of 12. Conclusion . This approach, based on strict magnetic resonance imaging data on the features of the pelvis allows to spare the anal sphincter preservation in patients with ultra-low tumors in the setting of challenging pelvic anatomy.
- 27 July 2026
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 7
Comparative analysis of intracorporeal and extracorporeal anastomotic techniques in laparoscopic right colectomy: assessment of surgical safety and short-term outcome
Background. Restoration of intestinal continuity after laparoscopic right colectomy may be performed with either intracorporeal (IA) or extracorporeal (EA) anastomosis. The surgical safety of IA remains under active investigation. The aim of this study was to evaluate the outcomes of IA in oncological patients undergoing laparoscopic right colectomy. Methods. A retrospective cohort study was conducted using a prospectively maintained database (June 2018 — December 2023), including patients with colon cancer who underwent laparoscopic right colectomy. Surgical outcomes were compared between the IA and EA groups. Results. A total of 701 patients were included: 649 in the IA group and 52 in the EA group. The groups were comparable in terms of age (p=0.353), sex (p=0.418), body mass index (p=0.583), and number of comorbidities (p=0.784). Earlier recovery of bowel function was observed in the IA group: median of 4 vs. 5 days to first stool (p<0.001). Anastomotic leak rates did not differ significantly between the IA and EA groups: 1.5% vs. 5.8% (p=0.065). Major postoperative complications (Clavien—Dindo ≥IIIA) occurred significantly less frequently with IA: 6.3% vs. 23.1% (p<0.001). IA was associated with a reduced risk of major complications, with an odds ratio of 0.31 (95% CI: 0.14—0.69) after adjustment for other factors. In subgroup analysis, the association between IA and fewer major postoperative complications was most pronounced in patients with obesity: odds ratio of 0.08 (95% CI: 0.02—0.30). Conclusion. Intracorporeal anastomosis in laparoscopic right colectomy is associated with faster recovery of bowel function, does not increase the risk of anastomotic leakage, and reduces the rate of major postoperative complications, particularly in patients with obesity. Mastery of the IA technique may become an important component of colorectal surgical training, offering patients a more favourable postoperative course.
- 27 July 2026
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 7
Comparative analysis of intracorporeal and extracorporeal anastomotic techniques in laparoscopic right colectomy: assessment of surgical safety and short-term outcome
Background. Restoration of intestinal continuity after laparoscopic right colectomy may be performed with either intracorporeal (IA) or extracorporeal (EA) anastomosis. The surgical safety of IA remains under active investigation. The aim of this study was to evaluate the outcomes of IA in oncological patients undergoing laparoscopic right colectomy. Methods. A retrospective cohort study was conducted using a prospectively maintained database (June 2018 — December 2023), including patients with colon cancer who underwent laparoscopic right colectomy. Surgical outcomes were compared between the IA and EA groups. Results. A total of 701 patients were included: 649 in the IA group and 52 in the EA group. The groups were comparable in terms of age (p=0.353), sex (p=0.418), body mass index (p=0.583), and number of comorbidities (p=0.784). Earlier recovery of bowel function was observed in the IA group: median of 4 vs. 5 days to first stool (p<0.001). Anastomotic leak rates did not differ significantly between the IA and EA groups: 1.5% vs. 5.8% (p=0.065). Major postoperative complications (Clavien—Dindo ≥IIIA) occurred significantly less frequently with IA: 6.3% vs. 23.1% (p<0.001). IA was associated with a reduced risk of major complications, with an odds ratio of 0.31 (95% CI: 0.14—0.69) after adjustment for other factors. In subgroup analysis, the association between IA and fewer major postoperative complications was most pronounced in patients with obesity: odds ratio of 0.08 (95% CI: 0.02—0.30). Conclusion. Intracorporeal anastomosis in laparoscopic right colectomy is associated with faster recovery of bowel function, does not increase the risk of anastomotic leakage, and reduces the rate of major postoperative complications, particularly in patients with obesity. Mastery of the IA technique may become an important component of colorectal surgical training, offering patients a more favourable postoperative course.
- Open Access
- 1 August 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (2) , 40-53
Results of treatment of patients with high and very high risk hepatoblastoma
Background. Hepatoblastoma (HB) is the most common malignant liver tumor in children aged 0–14 years. The introduction of intensive therapy based on alternating courses of cisplatin and carboplatin/doxorubicin, as well as dose-compression regimens of cisplatin administration, has significantly improved the prognosis in high-risk patients.The aim of the study – to assess the effectiveness of therapy in high-risk (HR) and very high-risk (VHR) patients with HB treated according to the International Group for Optimization of Therapy in Pediatric Liver Tumors (SIOPEL) protocols based on 2 major medical centers in the Russian Federation.Materials and methods. The study included patients with a verified diagnosis of HR and VHR HB, who received therapy at Dmitry Rogachev National Medical Research Center of the Pediatric Hematology, Oncology and Immunology and B.V. Petrovsky Russian Scientific Center of Surgery for the period 02.2012 to 07.2022 (125 months). The criteria of the SIOPEL group were used to stratify into risk groups. Until 2017, all patients were stratified into the HR group and received treatment according to the SIOPEL-4 protocol; since 2017, differentiated therapy has been carried out for patients in the HR group (SIOPEL-3 HR protocol) and VHR (SIOPEL-4 protocol). Since 2017, patients over 8 years of age have been stratified into VHR group. Survival was estimated using the Kaplan–Meier method. This study assessed overall survival (OS), event-free survival (EFS), and cumulative probability of death. Survival analysis was carried out as of 01.08.2023.Results. 49 patients with HR and VHR group HB aged 0 to 13 years were registered. The analysis included 47/49 (95.9 %) patients who received therapy according to the SIOPEL protocols. The median age at diagnosis was 24.9 months (range – 4.7–154.9). The male: female ratio was 1.47:1. Distribution by PRETEXT stage: PRETEXT II – 13 (27.6 %), PRETEXT III – 18 (38.3 %), PRETEXT IV – 16 (34.1 %) patients. The median α-fetoprotein level in patients with known exact values (n = 45) at the time of diagnosis was 182 431 (0.85–1 998 000) ng/ml. 24/47 (51 %) patients had initial lung metastases. The extent of delayed surgery: resection – 32 (68.1 %) patients, transplantation – 12 (25.5 %), without delayed surgery – 3 (6.4 %). Radicality of delayed surgery: R0 – 41/47 (87.2 %) patients, R1 – 3/47 (6.4 %), in 3/47 (6.4 %) patients the surgery wasn’t performed. Median follow-up 39.2 (2.5–129.2) months. Of the 47 patients included in the study, 37 (78.7 %) are alive, 10 (21.3 %) died (2/10 – surgical complications, 1/10 – infectious complications, 7/10 – progression of HB). Relapses/progressions were observed in 14/47 (29.8 %) patients, 7 (50 %) of whom died from disease progression. 3-year OS and EFS of the whole cohort (n = 47) were 80.1 ± 6.0 % and 64.9 ± 7.1 %. In the group of patients after liver transplantation (n = 12), 3-year OS and EFS were 73.3 ± 13.2 % and 64.2 ± 14.4%. The 3-year cumulative probability of death from the tumor was 16.7 ± 5.8 %. The 3-year cumulative probability of death from other causes was 7.2 ± 4.0 %. 3-year OS and EFS in the group of patients with distant metastases were 76.5 ± 9.4 % and 57.1 ± 10.3 %, in the group of patients without metastases 77.6 ± 8.8 % and 73.0 ± 9.4 %, respectively (p = 0,919 for OS; р = 0,440 for EFS).Conclusions. The data obtained in the study are consistent with the original studies of the SIOPEL group. The feasibility and effectiveness of incorporating liver transplantation into the treatment of patients with HB in the HR and VHR groups was confirmed.
- 1 August 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (2) , 40-53
Open AccessResults of treatment of patients with high and very high risk hepatoblastoma
Background. Hepatoblastoma (HB) is the most common malignant liver tumor in children aged 0–14 years. The introduction of intensive therapy based on alternating courses of cisplatin and carboplatin/doxorubicin, as well as dose-compression regimens of cisplatin administration, has significantly improved the prognosis in high-risk patients.The aim of the study – to assess the effectiveness of therapy in high-risk (HR) and very high-risk (VHR) patients with HB treated according to the International Group for Optimization of Therapy in Pediatric Liver Tumors (SIOPEL) protocols based on 2 major medical centers in the Russian Federation.Materials and methods. The study included patients with a verified diagnosis of HR and VHR HB, who received therapy at Dmitry Rogachev National Medical Research Center of the Pediatric Hematology, Oncology and Immunology and B.V. Petrovsky Russian Scientific Center of Surgery for the period 02.2012 to 07.2022 (125 months). The criteria of the SIOPEL group were used to stratify into risk groups. Until 2017, all patients were stratified into the HR group and received treatment according to the SIOPEL-4 protocol; since 2017, differentiated therapy has been carried out for patients in the HR group (SIOPEL-3 HR protocol) and VHR (SIOPEL-4 protocol). Since 2017, patients over 8 years of age have been stratified into VHR group. Survival was estimated using the Kaplan–Meier method. This study assessed overall survival (OS), event-free survival (EFS), and cumulative probability of death. Survival analysis was carried out as of 01.08.2023.Results. 49 patients with HR and VHR group HB aged 0 to 13 years were registered. The analysis included 47/49 (95.9 %) patients who received therapy according to the SIOPEL protocols. The median age at diagnosis was 24.9 months (range – 4.7–154.9). The male: female ratio was 1.47:1. Distribution by PRETEXT stage: PRETEXT II – 13 (27.6 %), PRETEXT III – 18 (38.3 %), PRETEXT IV – 16 (34.1 %) patients. The median α-fetoprotein level in patients with known exact values (n = 45) at the time of diagnosis was 182 431 (0.85–1 998 000) ng/ml. 24/47 (51 %) patients had initial lung metastases. The extent of delayed surgery: resection – 32 (68.1 %) patients, transplantation – 12 (25.5 %), without delayed surgery – 3 (6.4 %). Radicality of delayed surgery: R0 – 41/47 (87.2 %) patients, R1 – 3/47 (6.4 %), in 3/47 (6.4 %) patients the surgery wasn’t performed. Median follow-up 39.2 (2.5–129.2) months. Of the 47 patients included in the study, 37 (78.7 %) are alive, 10 (21.3 %) died (2/10 – surgical complications, 1/10 – infectious complications, 7/10 – progression of HB). Relapses/progressions were observed in 14/47 (29.8 %) patients, 7 (50 %) of whom died from disease progression. 3-year OS and EFS of the whole cohort (n = 47) were 80.1 ± 6.0 % and 64.9 ± 7.1 %. In the group of patients after liver transplantation (n = 12), 3-year OS and EFS were 73.3 ± 13.2 % and 64.2 ± 14.4%. The 3-year cumulative probability of death from the tumor was 16.7 ± 5.8 %. The 3-year cumulative probability of death from other causes was 7.2 ± 4.0 %. 3-year OS and EFS in the group of patients with distant metastases were 76.5 ± 9.4 % and 57.1 ± 10.3 %, in the group of patients without metastases 77.6 ± 8.8 % and 73.0 ± 9.4 %, respectively (p = 0,919 for OS; р = 0,440 for EFS).Conclusions. The data obtained in the study are consistent with the original studies of the SIOPEL group. The feasibility and effectiveness of incorporating liver transplantation into the treatment of patients with HB in the HR and VHR groups was confirmed.
- Open Access
- 26 December 2022
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 21 (4) , 31-44
Effectiveness of cisplatin monotherapy in standard-risk hepatoblastoma
Risk-adapted therapy is the standard of care for hepatoblastoma (HB). The aim of this study was to analyze the effectiveness of cisplatin monotherapy in patients with standard-risk HB. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. For the period 02.2012–12.2019 (95 months) 60 patients with standard-risk HB aged 0–8 years were treated within the framework of the cooperation of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation and B.V. Petrovsky Russian Scientific Center of Surgery. The SIOPEL criteria were used for stratification into risk groups. Throughout the study period, standard-risk patients received therapy per SIOPEL-3 SR protocol, including cisplatin monotherapy. Survival was assessed by the Kaplan–Meier method. For the purposes of this study, overall survival (OS), event-free survival (EFS), where any modification of chemotherapy regimen towards its escalation were considered as an additional event, and progression-free survival (PFS) were calculated. The survival analysis was carried out on 15.01.2021; 54/60 (90%) patients were treated with cisplatin monotherapy and included in the final analysis. Median age at diagnosis was 11.3 (range 0.0–87.7) months. Male:female ratio – 0.86:1. Distribution by PRETEXT stages: I – 14 (25.9%), II – 30 (55.6%), III – 10 (18.5%) patients. The median alphafetoprotein level at the time of diagnosis was 162 979 (range 129–2 000 000) ng/ml. Modification of therapy without confirmed relapse/progression was required in 3/54 patients. Median follow-up was 47.1 (range 2–99) months. Among 54 patients 52 (96.3%) are alive, 2 (3.7%) patients died (1/2 – complications of surgical treatment). Relapses/progressions were noted in 4/54 (7.4%) patients, one of whom died due to disease progression. The three-year OS was 98.1% (95% confidence interval (CI) 94.6–100), EFS – 85.1% (95% CI 75.5–94.6), PFS – 90.5% (95% CI 82.5–98.4). Our data are consistent with the original studies of the SIOPEL group and convincingly confirm the effectiveness of cisplatin monotherapy in patients with HB of the standard risk group in the Russian Federation. Currently this regimen is incorporated into the national clinical guidelines of HB therapy and considered as a standard of care.
- 26 December 2022
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 21 (4) , 31-44
Open AccessEffectiveness of cisplatin monotherapy in standard-risk hepatoblastoma
Risk-adapted therapy is the standard of care for hepatoblastoma (HB). The aim of this study was to analyze the effectiveness of cisplatin monotherapy in patients with standard-risk HB. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. For the period 02.2012–12.2019 (95 months) 60 patients with standard-risk HB aged 0–8 years were treated within the framework of the cooperation of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation and B.V. Petrovsky Russian Scientific Center of Surgery. The SIOPEL criteria were used for stratification into risk groups. Throughout the study period, standard-risk patients received therapy per SIOPEL-3 SR protocol, including cisplatin monotherapy. Survival was assessed by the Kaplan–Meier method. For the purposes of this study, overall survival (OS), event-free survival (EFS), where any modification of chemotherapy regimen towards its escalation were considered as an additional event, and progression-free survival (PFS) were calculated. The survival analysis was carried out on 15.01.2021; 54/60 (90%) patients were treated with cisplatin monotherapy and included in the final analysis. Median age at diagnosis was 11.3 (range 0.0–87.7) months. Male:female ratio – 0.86:1. Distribution by PRETEXT stages: I – 14 (25.9%), II – 30 (55.6%), III – 10 (18.5%) patients. The median alphafetoprotein level at the time of diagnosis was 162 979 (range 129–2 000 000) ng/ml. Modification of therapy without confirmed relapse/progression was required in 3/54 patients. Median follow-up was 47.1 (range 2–99) months. Among 54 patients 52 (96.3%) are alive, 2 (3.7%) patients died (1/2 – complications of surgical treatment). Relapses/progressions were noted in 4/54 (7.4%) patients, one of whom died due to disease progression. The three-year OS was 98.1% (95% confidence interval (CI) 94.6–100), EFS – 85.1% (95% CI 75.5–94.6), PFS – 90.5% (95% CI 82.5–98.4). Our data are consistent with the original studies of the SIOPEL group and convincingly confirm the effectiveness of cisplatin monotherapy in patients with HB of the standard risk group in the Russian Federation. Currently this regimen is incorporated into the national clinical guidelines of HB therapy and considered as a standard of care.
- Open Access
- 28 March 2020
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 19 (1) , 92-99-99
Combined hepatoblastoma and yolk sac tumor of the liver
A 6-year-old patient was admitted to the Petrovsky National Research Center of Surgery in Moscow, diagnosed with hepatoblastoma (HB) of the right lobe of the liver and after undergoing 4 cycles of SIOPEL (super PLADO) pre-operative chemotherapy. An immunohistochemistry test, performed after liver resection, revealed a rare combination of mixed epithelial and mesenchymal hepatoblastoma and yolk sac tumor. The epithelial component of HB consisted of highly differentiated fetal cells, while the mesenchymal component consisted of osteoid. The morphological structure of the second lesion corresponded to yolk sac tumor. Both tumors had regressive changes conditioned by chemotherapy: these changes were most pronounced in HB. In the highly differentiated fetal component of HB it was possible to detect a weak focal perinuclear alpha-fetoprotein expression, HepPar expression, membranous expression of beta-catenin and diffuse glutamine synthetase expression. Mitotic figures were not determined. The node of the yolk sac tumor had the characteristic histological structure of an endodermal sinus tumor with a hepatoid component. In the main tumor node and its nodular elements in the fibrovascular stroma it was possible to identify alpha-fetoprotein expression, CD34, nuclear and cytoplasmic expression of beta-catenin, CDX2, as well as a rare expression of PLAP and multi-cytokeratin, and mitotic activity was high (21 in 10 high power fields, 400x magnification). In the existing literature available to us, there is only one observation of combined hepatoblastoma and yolk sac tumor. Parents patients agreed to use personal data, including the fotos, in research and publications.
- 28 March 2020
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 19 (1) , 92-99-99
Open AccessCombined hepatoblastoma and yolk sac tumor of the liver
A 6-year-old patient was admitted to the Petrovsky National Research Center of Surgery in Moscow, diagnosed with hepatoblastoma (HB) of the right lobe of the liver and after undergoing 4 cycles of SIOPEL (super PLADO) pre-operative chemotherapy. An immunohistochemistry test, performed after liver resection, revealed a rare combination of mixed epithelial and mesenchymal hepatoblastoma and yolk sac tumor. The epithelial component of HB consisted of highly differentiated fetal cells, while the mesenchymal component consisted of osteoid. The morphological structure of the second lesion corresponded to yolk sac tumor. Both tumors had regressive changes conditioned by chemotherapy: these changes were most pronounced in HB. In the highly differentiated fetal component of HB it was possible to detect a weak focal perinuclear alpha-fetoprotein expression, HepPar expression, membranous expression of beta-catenin and diffuse glutamine synthetase expression. Mitotic figures were not determined. The node of the yolk sac tumor had the characteristic histological structure of an endodermal sinus tumor with a hepatoid component. In the main tumor node and its nodular elements in the fibrovascular stroma it was possible to identify alpha-fetoprotein expression, CD34, nuclear and cytoplasmic expression of beta-catenin, CDX2, as well as a rare expression of PLAP and multi-cytokeratin, and mitotic activity was high (21 in 10 high power fields, 400x magnification). In the existing literature available to us, there is only one observation of combined hepatoblastoma and yolk sac tumor. Parents patients agreed to use personal data, including the fotos, in research and publications.
- 12 August 2019
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 98 (4)
ALPHA-FETOPROTEIN KINETICS IN PATIENTS WITH HEPATOBLASTOMA OF THE STANDARD RISK GROUP ON THE BACKGROUND OF COMBINED ANTITUMOR THERAPY
Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.
- 12 August 2019
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 98 (4)
ALPHA-FETOPROTEIN KINETICS IN PATIENTS WITH HEPATOBLASTOMA OF THE STANDARD RISK GROUP ON THE BACKGROUND OF COMBINED ANTITUMOR THERAPY
Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.